As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based biotechnology pioneer is currently grappling with a market valuation that has retreated nearly 93% from its 2021 peaks. The focus of the investment community has [...]
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare sector during the peak of the COVID-19 crisis, the pharmaceutical giant is currently navigating one of the most challenging chapters in its [...]
As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global pandemic, the company is now deep into its "Act 2"—a pivot from a single-product powerhouse to a diversified platform focused on oncology, latent viruses, [...]
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
The S&P 500 index has concluded 2025 on a historic high, defying early-year skepticism and navigating significant geopolitical shifts to reach unprecedented levels. As of the final full week of trading in December, the benchmark index breached the psychological barrier of 6,900, closing at a record 6,932.
Looking for the S&P500 stocks that are experiencing notable gaps on Friday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of transition for the pharmaceutical giant. The guidance, which highlights the dual pressures of declining COVID-19 product demand and
Let's delve into the developments on the US markets one hour before the close of the markets on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Tuesday. Discover the gap up and gap down stocks in the S&P500 index.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 7.8% in the afternoon session after the stock's positive momentum continued as the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would invest up to $54.3 million to support a pivotal Phase 3 clinical trial for the company's investigational mRNA-based pandemic influenza vaccine candidate, mRNA-1018.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a late-stage trial for its experimental bird flu vaccine.
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall Street's expectations. The announcement immediately sent shockwaves through the market, with Pfizer's stock experiencing a notable decline as investors
Rapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
